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Abstract
Aims/hypothesis Hypoadiponectinaemia and raised
C-reactive protein (CRP) level are obesity-related biomarkers
associated with glucose dysregulation. We evaluated the
combined use of these two biomarkers in predicting the
deterioration of glycaemia in a prospective study after a
median of 5.4 years.
Methods In total 1,288 non-diabetic participants from the
Hong Kong Cardiovascular Risk Factor Prevalence Study-2,
with high-sensitivity CRP (hsCRP) and total adiponectin
levels measured were included. OGTT was performed in
all participants. Two hundred and six participants had
deterioration of glycaemia at follow-up, whereas 1,082
participants did not.
Results Baseline age, hsCRP and adiponectin levels were
significant independent predictors of the deterioration of
glycaemia in a Cox regression analysis after adjusting for
baseline age, sex, BMI, hypertension, triacylglycerols, 2 h
post-OGTT glucose and homeostasis model assessment of
insulin resistance index (all p<0.01). The introduction of
hsCRP or adiponectin level to a regression model including
the other biomarker improved the prediction of glycaemic
progression significantly in all participants, especially in
women (all p<0.01). The combined inclusion of the two
biomarkers resulted in a modest improvement in model
discrimination, compared with the inclusion of either one
alone. Among participants with impaired fasting glucose/
impaired glucose tolerance (IFG/IGT) at baseline, hsCRP
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Conclusions/interpretation Adiponectin and hsCRP levels
are independent factors in predicting the deterioration of
glycaemia, supporting the role of adiposity-related inflam-
mation in the development of type 2 diabetes. Their
combined use as predictive biomarkers is especially useful
in women, but not in participants with IFG/IGT.
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Glycaemia
Abbreviations
CRISPS Hong Kong Cardiovascular Risk Factor
Prevalence Study
CRP C-reactive protein
HMW High molecular weight
hsCRP High-sensitivity C-reactive protein
HOMA-IR HOMA of insulin resistance index
IFG Impaired fasting glucose
IGT Impaired glucose tolerance
NGT Normal glucose tolerance
Introduction
The prevalence of obesity is increasing and has become a
major global burden on public health. Obesity is known to
cause the deterioration of glycaemia, leading eventually to
diabetes. Adipose tissue has been recognised as an endocrine
organ in addition to its role in lipid storage and mobilisation
[1]. In obese individuals, there is an excess of ectopic fat
deposition at undesirable sites such as liver, skeletal muscle
and heart [1]. The excess adiposity is associated with
dysregulated secretion of various adipokines [1]. Adiponec-
tin is one of the most abundant and well-studied adipokines.
It is secreted exclusively from adipose tissue with direct
insulin-sensitising, anti-atherogenic and anti-inflammatory
properties [2, 3]. Circulating level of adiponectin is lower in
individuals with obesity [4] and type 2 diabetes [5]. In
prospective studies, hypoadiponectinaemia can predict the
development of type 2 diabetes in Chinese [6], Pima Indians
[7] and whites [8].
An increase in adipose tissue mass is often associated
with inflammation due to macrophage infiltration. Chronic
inflammation in adipose tissue contributes to the develop-
ment of insulin resistance through increased secretion of
inflammatory cytokines such as IL-6 and TNF-α from
adipocytes and activated macrophages [3]. In humans,
plasma level of C-reactive protein (CRP), a cytokine
downstream of TNF-α a n dI L - 6i nt h ei n f l a m m a t o r y
cascade and a marker of chronic inflammation, correlates
positively with body fat mass, visceral adipose tissue
accumulation and plasma insulin [9]. In prospective studies,
raised CRP levels, measured with a high-sensitivity assay
(hsCRP), predict the development of type 2 diabetes in both
Chinese [10] and white [11, 12] people.
Although previous studies have demonstrated that either
hypoadiponectinaemia or raised hsCRP level could predict
the deterioration of glycaemia [6–8, 10–12], it remains
uncertain whether these two biomarkers are useful in
predicting glycaemic progression in the general Chinese
population, over and above conventional risk factors such
as age, sex, BMI or waist circumference, insulin resistance
and baseline plasma glucose. It is also not known whether
the combined use of these two biomarkers could improve
on the prediction of glycaemic progression, vs the use of
either alone. Such studies in Chinese are especially indicated
in view of ethnic differences in visceral adiposity and hsCRP
level.Comparedwithwhite people,Asian peopleoften havea
greater degree of visceral adiposity and higher risk of type 2
diabetes for the same BMI [13], but have lower hsCRP level
[14]. In fact, a recent study from the European Prospective
Investigation of Cancer (EPIC)-Norfolk population-based
cohort showed that the association of baseline hsCRP level
with incident diabetes after a mean follow-up of 3.7 years
could be due to the effect of confounding factors, including
adiposity and adiponectin [15].
We hypothesised that the measurement of both adipo-
nectin and hsCRP , which exert opposite effects on systemic
inflammation [2, 3], will provide a better index of obesity-
related inflammatory changes, now recognised to play a
key role in the pathogenesis of type 2 diabetes. Therefore,
in this study, we examined, in a prospective study of
unrelated, non-diabetic Chinese people, the combined use
of the levels of these two biomarkers, adiponectin and
hsCRP , in predicting the deterioration of glycaemia after a
median interval of 5.4 years, and whether they can improve
the prediction based on conventional risk factors.
Methods
Study participants The Hong Kong Cardiovascular Risk
Factor Prevalence Study (CRISPS) is a population-based
prospective cohort study of cardiovascular risk factors in
Hong Kong Chinese [16]. In 1995–1996 (CRISPS-1), a
random sample of 2,895 Hong Kong Chinese participants,
representative of the general population, was recruited
through random telephone numbers. In 2000–2004, 1,944
participants were followed up in CRISPS-2 [16]. The study
protocol was approved by the Ethics Committee of the
University of Hong Kong. All participants gave written
consent.
Among 1,619 non-diabetic participants in CRISPS-2
(baseline), 1,307 participants had been followed up in
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median follow-up period of 5.4 years (6,706.3 person-
years). Among them, hsCRP and adiponectin levels were
measured in 1,298 participants. After further excluding 10
participants with hsCRP level >10 mg/l, which was
considered to reflect clinical inflammation, a total of
1,288 participants (6,621.9 person-years) were included in
this analysis. There were 886 participants with their
glycaemic status (normal glucose tolerance [NGT] or
impaired fasting glucose [IFG]/impaired glucose tolerance
[IGT]) remaining unchanged, 206 participants with deteri-
oration of glycaemia (i.e. from NGT to IFG/IGT or
diabetes, or from IFG/IGT to diabetes) and 196 participants
with improved glycaemia (from IFG/IGT to NGT).
V ariables of interest The study procedures in CRISPS,
including the measurement of blood pressure, body weight,
height and waist circumference on the assessment days,
have been described previously [16]. OGTTwas performed
in all the included participants at both baseline and follow-
up, except those taking glucose-lowering medication.
Diabetes was defined as fasting glucose ≥7.0 mmol/l, 2 h
glucose ≥11.1 mmol/l after OGTT or the use of glucose-
lowering medication [17]. IFG/IGT was defined as fasting
glucose of 5.6–6.9 mmol/l or 2 h post-OGTT glucose of
7.8–11.0 mmol/l in non-diabetic participants [17]. Total
adiponectin (intra-assay and inter-assay coefficients of
variation of 6.2–8.3% and 5.1–6.4% respectively) and
hsCRP levels (intra-assay and inter-assay coefficients of
variation of 2.7–4.8% and 3.6–5.5%, respectively) were
measured using in-house sandwich ELISA established in
our laboratory (Antibody and Immunoassay Services [AIS],
www.antibody.hku.hk). Details on the measurement of
biochemical variables have been described previously
[16]. Age, sex, smoking, drinking, drug medication and
family history of diabetes were obtained using a stand-
ardised questionnaire. BMI was calculated as weight (kg)
divided by the square of height (m), and waist circumfer-
ence was measured halfway between the xiphisternum and
the umbilicus. Hypertension was defined as blood pressure
≥140/90 mmHg or the use of antihypertensive medication.
Regular drinking was defined as consumption of alcoholic
drinks at least once a week.
Statistical analysis Statistical analysis was performed using
SPSS 18.0 (SPSS Inc., Chicago, IL, USA). Data are
presented as mean±SD or geometric mean (95% CI).
V ariables with skewed distributions were log-transformed
before analysis. Baseline characteristics were compared
after adjusting for age and sex. Multiple Cox regression
models were used to estimate the HR for the deterioration
of glycaemia over a median of 5.4 years. Baseline variables
were used as covariates in the regression model if they were
biologically likely to affect glycaemia or were significantly
different between participants with and without glycaemic
progression. The improvement in model discrimination by
the addition of hsCRP , adiponectin, or both as the
independent variables was assessed by the log-likelihood
ratio test and c-statistics (mathematically equivalent to areas
under ROC [receiver operating characteristic] curves in
binary outcomes) [18]. For variables that were highly
correlated such as BMI and waist circumference, only
one was entered into the regression analysis. The
p values for interaction were estimated by including each
multiplicative interaction term in the multivariate regres-
sion models in full sample after adjusting for the main
effects of all covariates.
Results
Table 1 shows the baseline clinical characteristics of
participants with and without deterioration of glycaemia
after a median interval of 5.4 years. A total of 134 and 17
participants with NGT at baseline had developed IFG/IGT
and diabetes at follow-up, respectively, whereas 55 partic-
ipants with IFG/IGT at baseline had developed diabetes at
follow-up. There were 713 participants with NGT at both
visits and 173 participants with IFG/IGT at both visits. A
total of 196 participants with IFG/IGTat baseline reverted to
NGTat follow-up. Participants with deterioration of glycae-
mia had significantly higher age, BMI, waist circumference,
prevalence of hypertension, plasma triacylglycerols, 2 h
post-OGTT glucose, fasting insulin, HOMA of insulin
resistance index (HOMA-IR) and hsCRP level. The percen-
tages of those taking lipid-lowering and antihypertensive
medications were also higher in participants with deteriora-
tion of glycaemia. Participants with deterioration of glycae-
mia had significantly lower baseline adiponectin level in
women, but not in men. There was no significant difference
in fasting glucose.
In multiple Cox regression analysis (Table 2), only
baseline age was a significant independent predictor of the
deterioration of glycaemia, but not sex, BMI, hypertension,
triacylglycerols, 2 h post-OGTT glucose and HOMA-IR
(model 1). When baseline hsCRP and adiponectin levels
were included in the model, they both showed significant
association with the deterioration of glycaemia, together
with baseline age (model 2). The same three independent
predictors were observed if BMI was replaced by waist
circumference in the regression model (p<0.001 for age,
p<0.001 for hsCRP level and p=0.007 for adiponectin
level). In a separate analysis, both hsCRP and adiponectin
levels were still significant independent predictors, if
HOMA-IR was replaced by fasting insulin (p=0.001 and
2554 Diabetologia (2011) 54:2552–25600.008 respectively). Figure 1 shows the percentage of
participants with deterioration of glycaemia according to
the baseline hsCRP and adiponectin levels.
In a Cox regression model with age, sex, BMI,
hypertension, triacylglycerols, 2 h post-OGTT glucose and
HOMA-IR (model A), the introduction of either biomarker,
hsCRP or adiponectin level, or both could significantly
improve the prediction of the deterioration of glycaemia
(Table 3). The introduction of both hsCRP and adiponectin
levels increased the c-statistics by 0.014 (Table 3). The
introduction of hsCRP or adiponectin level to a model
including the other biomarker resulted in a significant
improvement in the prediction of glycaemic progression
(p<0.01, see electronic supplementary material [ESM]
Table 1). Similar results were obtained if BMI was replaced
by waist circumference in the regression model (model B)
or if HOMA-IR was replaced by fasting insulin (model C)
(Table 3 and ESM Table 1).
There was no significant interaction between hsCRP
and adiponectin levels in models A, B and C (p for
Baseline variable Without deterioration
(n=1,082)
With deterioration
(n=206)
p value
Age (years) 49.4±10.8 53.5±10.9 <0.001
Women (%) 55.5 52.9 0.761
BMI (kg/m
2) 23.7±3.3 24.6±3.4 0.001
Waist circumference (cm) 78.3±9.5 81.2±9.8 0.001
Systolic blood pressure (mmHg)
a 116.8±15.5 120.6±16.9 0.438
Diastolic blood pressure (mmHg)
a 73.6±9.9 74.9±9.6 0.147
Hypertension (%) 20.5 34.5 0.016
LDL-cholesterol (mmol/l) 3.24±0.78 3.37±0.83 0.165
HDL-cholesterol (mmol/l) 1.39±0.35 1.39±0.35 0.069
Triacylglycerols (mmol/l)
b 1.09 (1.06,1.13) 1.22 (1.14,1.31) 0.030
Fasting glucose (mmol/l) 5.03±0.47 5.13±0.50 0.110
2 h post-OGTT glucose (mmol/l) 6.54±1.65 7.02±1.60 0.007
Fasting insulin (pmol/l)
b 48.9 (47.4,50.5) 54.8 (51.1,58.9) 0.004
HOMA-IR
b 1.56 (1.51,1.62) 1.79 (1.66,1.93) 0.002
Family history of diabetes (%) 30.6 34.0 0.067
Adiponectin (mg/l)
b 0.002
Men 5.69 (5.39,6.00) 5.72 (5.08,6.44) 0.268
Women 8.04 (7.69,8.41) 6.78 (6.20,7.86) 0.001
hsCRP (mg/l)
b 0.60 (0.56,0.64) 0.89 (0.78,1.02) <0.001
Current smoking (%) 15.4 16.5 0.700
Regular drinking (%) 9.7 11.8 0.514
Lipid-lowering medication (%) 2.5 7.3 0.010
Antihypertensive medication (%) 10.4 21.4 0.004
Table 1 Baseline characteristics
of participants with and
without deterioration of glycae-
mia after a median interval
of 5.4 years
Data are expressed as mean±SD
unless stated otherwise
a156 individuals on antihyperten-
sive medication were excluded
bData are expressed as geomet-
ric mean (95% CI) due to
skewed distributions
All p values were adjusted for
age and sex, except for age
(adjusted for sex only) and sex
(adjusted for age only)
Baseline variable Model 1 Model 2
HR (95% CI) p value HR (95% CI) p value
Age (years) 1.03 (1.02,1.05) <0.001 1.03 (1.02,1.05) <0.001
Female sex 1.06 (0.80,1.41) 0.689 1.15 (0.86,1.55) 0.349
BMI (kg/m
2) 1.02 (0.98,1.07) 0.308 0.99 (0.95,1.04) 0.781
Hypertension 1.29 (0.93,1.81) 0.132 1.24 (0.88,1.74) 0.213
Triacylglycerols (mmol/l)
a 1.11 (0.95,1.29) 0.187 1.05 (0.90,1.23) 0.545
2 h post-OGTT glucose (mmol/l) 1.03 (0.94,1.12) 0.558 1.01 (0.92,1.10) 0.817
HOMA-IR
a 1.09 (0.92,1.28) 0.318 1.05 (0.89,1.24) 0.548
Adiponectin (mg/l)
a –– 0.80 (0.68,0.95) 0.008
hsCRP (mg/l)
a –– 1.30 (1.11,1.52) 0.001
Table 2 Multiple Cox regres-
sion analysis showing baseline
variables independently associ-
ated with the deterioration of
glycaemia over a median of
5.4 years
aData were log-transformed be-
fore analysis and HRs are
expressed in terms of per SD of
log-transformed unit
Diabetologia (2011) 54:2552–2560 2555interaction >0.88). However, there was a trend of
interaction between sex and adiponectin level with a
marginally non-significant p v a l u eo f0 . 0 6i na l lt h et h r e e
models. Sex-specific analysis was therefore performed,
showing that the greater predicted risks were largely
contributed by the effects in women (ESM Table 1). In
model A with hsCRP level, the improvement in the
prediction by the introduction of adiponectin level did
not reach statistical significance in men (p=0.814). Similar
results were obtained in models B and C (data not shown).
We then investigated whether the prediction of hsCRP
and adiponectin levels differed between participants with
NGT and IFG/IGT at baseline. Among participants with
NGTat baseline, the introduction of hsCRP level, but not
adiponectin level resulted in a significant improvement in
the prediction of glycaemic progression (Table 4). In sex-
specific analysis, the introduction of hsCRP , adiponectin or
both levels resulted in a significant improvement in the
prediction of glycaemic progression in women (c-statistics
increased by 0.015–0.032), but not in men (Table 4). In
women, the introduction of hsCRP level to a model with
adiponectin level could increase the likelihood ratio by
8.878 (p=0.003), whereas the introduction of adiponectin
level to a model with hsCRP level could increase the
Fig. 1 A three-dimensional bar chart showing the percentage of
participants with deterioration of glycaemia after a median interval of
5.4 years according to the baseline hsCRP and adiponectin levels. The
median of hsCRP level was 0.66 mg/l. As adiponectin level differed
significantly with sex (p<0.001), sex-specific median was used, which
was 5.80 mg/l in men and 8.08 mg/l in women
Table 3 Cox regression analysis of baseline hsCRP and adiponectin levels in the deterioration of glycaemia over a median of 5.4 years
Model Baseline variable HR (95% CI) Likelihood ratio p value c-statistic
hsCRP Adiponectin
Model A
Null No hsCRP and adiponectin –– –– 0.541
1 + hsCRP 1.32 (1.13,1.55) – 12.291
a <0.001 0.551
2 + adiponectin – 0.79 (0.67,0.92) 8.356
a 0.004 0.546
3 + hsCRP + adiponectin 1.30 (1.11,1.52) 0.80 (0.68, 0.95) 19.108
b <0.001 0.555
Model B
Null No hsCRP and adiponectin –– –– 0.539
1 + hsCRP 1.35 (1.15,1.57) – 14.121
a <0.001 0.550
2 + adiponectin – 0.78 (0.66,0.92) 8.965
a 0.003 0.544
3 + hsCRP + adiponectin 1.32 (1.13,1.54) 0.80 (0.68,0.94) 21.162
b <0.001 0.553
Model C
Null No hsCRP and adiponectin –– –– 0.541
1 + hsCRP 1.32 (1.13,1.54) – 11.929
a 0.001 0.551
2 + adiponectin – 0.79 (0.67,0.92) 8.312
a 0.004 0.546
3 + hsCRP + adiponectin 1.30 (1.11,1.52) 0.80 (0.68,0.94) 18.807
b <0.001 0.554
Model A: Age, sex, BMI, hypertension, triacylglycerols, 2 h post-OGTT glucose and HOMA-IR were included
Model B: BMI in model Awas replaced by waist circumference
Model C: HOMA-IR in model Awas replaced by fasting insulin
Triacylglycerols, HOMA-IR, insulin, hsCRP and adiponectin levels were log-transformed before analysis. HRs are expressed in terms of per SD
of log-transformed unit
aModels 1 and 2 were compared with the null model by χ
2 (df=1)
bModel 3 was compared with the null model by χ
2 (df=2)
2556 Diabetologia (2011) 54:2552–2560likelihood ratio by 4.987 (p=0.026). On the other hand,
among participants with IFG/IGT at baseline, the intro-
duction of hsCRP , adiponectin or both levels could not
improve the prediction of glycaemic progression from
IFG/IGT to diabetes significantly (Table 4). As the number
of participants with glycaemic progression was small, we
assessed the glycaemic improvement among participants
with IFG/IGT at baseline. In this separate analysis, the
introduction of hsCRP , adiponectin or both levels still
could not improve the prediction of glycaemic improvement
significantly (Table 4). In both analyses of participants with
IFG/IGT at baseline, similar non-significant results were
obtained in sex-specific analysis (data not shown). In all
these analysis, similar results were obtained if BMI was
replaced by waist circumference in the Cox regression
models or if HOMA-IR was replaced by fasting insulin
(data not shown).
Discussion
This report is the first study to evaluate the combined use
of hsCRP and total adiponectin on the prediction of
glycaemic progression in Chinese. In this study, raised
hsCRP and reduced adiponectin levels were found to be
associated with glycaemic progression, consistent with
what we and others have previously reported [6–8, 10–
12]. We also further demonstrated, in a general population,
that their usefulness as independent biomarkers for
predicting the deterioration of glycaemia, over a median
interval of 5.4 years, was over and above those of
conventional risk factors such as age, sex, BMI, insulin
resistance and baseline 2 h post-OGTT glucose. Further-
more, we have shown that the combined use of these two
biomarkers resulted in an improvement in risk prediction,
compared with the use of either on its own, especially in
Table 4 Cox regression analysis of baseline hsCRP and adiponectin levels in the change of glycaemia over a median of 5.4 years according to the
glycaemic status at baseline
V ariable Model Baseline variables HR (95% CI) Likelihood ratio p value c-statistic
hsCRP Adiponectin
NGT→NGT (control, n=713) vs NGT→IFG/IGT/diabetes (case, n=151)
Overall (n=864) Null No hsCRP and adiponectin –––– 0.621
1 + hsCRP 1.27 (1.05,1.52) – 6.375
a 0.012 0.628
2 + Adiponectin – 0.86 (0.71,1.04) 2.468
a 0.116 0.621
3 + hsCRP+adiponectin 0.87 (0.72,1.05) 1.26 (1.05,1.51) 8.460
b 0.015 0.628
Men (n=363) Null No hsCRP and adiponectin –––– 0.658
1 + hsCRP 1.19 (0.92,1.54) – 1.855
a 0.173 0.660
2 + Adiponectin – 1.81 (0.86,1.62) 1.073
a 0.300 0.664
3 + hsCRP+adiponectin 1.20 (0.88,1.64) 1.21 (0.93,1.56) 3.145
b 0.208 0.666
Women (n=501) Null No hsCRP and adiponectin –––– 0.610
1 + hsCRP 1.34 (1.03,1.74) – 4.762
a 0.029 0.626
2 + Adiponectin – 0.70 (0.56,0.88) 8.653
a 0.003 0.625
3 + hsCRP+adiponectin 1.35 (1.04,1.75) 0.70 (0.56,0.88) 13.641
b 0.001 0.642
IFG/IGT→IFG/IGT (control, n=173) vs IFG/IGT→diabetes (case, n=55)
Null No hsCRP and adiponectin –––– 0.544
1 + hsCRP 1.09 (0.81,1.45) – 0.317
a 0.573 0.544
2 + Adiponectin – 0.73 (0.53,1.01) 3.528
a 0.060 0.555
3 + hsCRP+adiponectin 1.05 (0.79,1.41) 0.74 (0.54,1.02) 3.643
b 0.162 0.555
IFG/IGT→IFG/IGT (control, n=173) vs IFG/IGT→NGT (case, n=196)
Null No hsCRP and adiponectin –––– 0.574
1 + hsCRP 1.04 (0.89,1.21) – 0.252
a 0.616 0.572
2 + Adiponectin – 0.93 (0.78,1.10) 0.672
a 0.412 0.573
3 + hsCRP + adiponectin 1.04 (0.89,1.21) 0.93 (0.79,1.11) 0.903
b 0.637 0.571
Age, sex (except in sex-specific subgroups), BMI, hypertension, triacylglycerols, 2 h post-OGTT glucose and HOMA-IR were included in all
models
Triacylglycerols, HOMA-IR, insulin, hsCRP , and adiponectin levels were log-transformed before analysis. HRs are expressed in term of per SD of
log-transformed unit
aModels 1 and 2 were compared with the null model by χ
2 (df=1);
bmodel 3 was compared with the null model by χ
2 (df=2)
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Therefore, the combined use of hsCRP and adiponectin levels
can help to identify participants at higher future risk of
deterioration of glycaemia and type 2 diabetes in Chinese
people, especially in women with NGT. Our findings also
highlight the role of adiposity-related inflammation in the
development of type 2 diabetes.
Adiponectin possesses anti-inflammatory properties [2,
3]. Previous cell culture studies have shown that adiponec-
tin can suppress CRP synthesis and secretion from aortic
endothelial cells and hepatocytes [19]. On the other hand,
CRP can also suppress adiponectin expression and secre-
tion from adipocytes [20]. In our population, adiponectin
level correlates negatively with hsCRP level [21]. However,
in this study, we did not find any interaction between
hsCRP and adiponectin levels on the deterioration of
glycaemia.
The independent effect of hsCRP and adiponectin
levels on glycaemia is consistent with some previous
studies. For example, the metabolic syndrome is a risk
factor of type 2 diabetes [16] and hypoadiponectinaemia
is associated with prevalent metabolic syndrome indepen-
dent of age, sex, BMI and fasting insulin [22], or even
after adjusting for inflammatory markers such as hsCRP
level [23]. In a cross-sectional Japanese study, both hsCRP
and high molecular weight (HMW) adiponectin (the active
form of adiponectin) levels showed independent effect in
the association with the metabolic syndrome [24]. In
another Japanese study, the ratio of hsCRP to HMW
adiponectin levels was more associated with insulin
resistance than either hsCRP or HMW adiponectin level
alone [25]. However, hypoadiponectinaemia, but not
raised hsCRP level, predicted future risk of type 2 diabetes
in Pima Indians [26], and the association of hsCRP level
with incident diabetes could be contributed at least partly
by adiponectin level in a study of white people [15]. There
is only one previous study that investigated the combined
effect of hsCRP and adiponectin levels on the risk of
developing diabetes. In that Aboriginal Canadian study,
hypoadiponectinaemia, but not raised hsCRP level, pre-
dicted incident type 2 diabetes and their combination did
not improve diabetes prediction [27]. However, in that
study, 22.2% of participants had their diabetes outcome
obtained from self-reported questionnaire. The discrepan-
cy between these and our study could be partly attributed
to the differences in study power and characteristics of the
study participants. Nevertheless, the predictive ability of
hsCRP level seems to be stronger in Asian than in white
people, whereas adiponectin level gives good prediction in
both ethnicities. In fact, adiposity and insulin resistance
have been found to be the major confounding factors,
together with age, smoking and hypertension for the
prediction of hsCRP levels with incident diabetes or
glycaemic progression in whites, Aboriginal Canadians
and Pima Indians [15, 26–30]. In our study, these
confounding factors were not associated with glycaemic
progression, except age. This difference could be attribut-
ed to the ethnic differences in visceral adiposity and
hsCRP level [13, 14] .I th a sb e e nr e p o r t e dt h a tC h i n e s e
people have a greater amount of visceral adipose tissue
than whites and this difference does not exist between
white people and Aboriginal Canadians [31]. Even among
Asians, the association of hsCRP level with IFG or
elevated level of glycated haemoglobin is stronger in
Chinese people than in Malay and Indian non-diabetic
individuals [32].
In our study, the independent effect of hsCRP and
adiponectin levels was only found in women, but not in
men. This may be partly due to the sex difference in the
pattern of fat accumulation and greater effect of body fat on
subclinical inflammation in women [33]. Moreover, raised
levels of inflammatory markers such as hsCRP and IL-6 are
more predictive of future risk of type 2 diabetes in women
than in men [34]. As the progression from NGT to IFG/IGT
or diabetes mellitus may not be the same as that from IFG/
IGT to diabetes mellitus, we also investigated the combi-
nation effect of hsCRP and adiponectin levels according to
the baseline glycaemic status. In this analysis, neither
hsCRP nor adiponectin levels showed independent effect
among participants with IFG/IGTat baseline. The improve-
ment in risk prediction with the combined use of these two
biomarkers was more prominent in women with NGT at
baseline. The reason for this is speculative. Subjects with
IFG/IGT already have elevated hsCRP and reduced adipo-
nectin levels. Therefore, these variables may not have the
ability to predict the further changes in glycaemic status.
Moreover, the situation may also be further complicated by
the finding of a recent study, showing that hyperglycaemia
could increase CRP secretion from human macrophages
[35].
Our study was limited by the relatively small number
of participants with the deterioration of glycaemia as the
participants were recruited from the general population.
However, this is the largest prospective study investi-
gating the combined effect of hsCRP and adiponectin
levels on glycaemia. As there are ethnic differences in
visceral adiposity, hsCRP levels and prediction of
hsCRP for glycaemic progression [13, 14, 31, 32], our
findings may not be generalised to populations of other
ethnicities and may need to be confirmed in other
independent cohorts with larger sample size and different
ethnic groups.
In conclusion, adiponectin and hsCRP levels indepen-
dently predict the deterioration of glycaemia. Using both
biomarkers improves the prediction, especially in women,
but not in participants with IFG/NGT.
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